Kassi Filkins

Catch up on this week's highlights in retina.

The newly approved technology delivers low-dose microcurrents through closed eyelids to stimulate retinal cells.

Luxa Biotechnology reveals promising phase 1/2a trial results for RPESC-RPE therapy, showing safety and potential vision restoration in patients with dry AMD.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

Catch up on this week's highlights in retina.

Kodiak Sciences reveals promising APEX study results for KSI-101, showing significant vision improvement in macular edema patients.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

Catch up on this week's highlights in retina.

Sanofi's gene therapy SAR402663 receives FDA fast track designation, targeting neovascular age-related macular degeneration with positive clinical trial data.

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared with nonpregnant controls.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

BVI launches Virtuoso, a groundbreaking dual-function surgical platform for cataract and vitreoretinal procedures, enhancing efficiency and control in surgery.

Leading companies to unveil new research on retinal diseases at EURETINA 2025, showcasing innovative therapies and clinical trial results.

Catch up on this week's highlights in retina.

Advancements in retinal therapies and technologies are scheduled to be showcased at EURETINA 2025 from Clearside, ZEISS, and Ashvattha Therapeutics.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Catch up on this week's highlights in retina.

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Catch up on this week's highlights in retina.

Neurotech Pharmaceuticals performs the first ENCELTO procedure.

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Catch up on this week's highlights in retina.

Avant Technologies and Ainnova Tech refine clinical trial protocol for Vision AI platform, aiming for FDA 510(k) approval to enhance diabetic retinopathy detection.

Genentech reveals five-year data showing Susvimo effectively maintains vision in wet AMD patients with fewer injections, offering a promising treatment alternative.

Catch up on this week's highlights in retina.